- Home
- CRT vs XGN Comparison
CRT vs XGN Comparison
Compare CRT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- XGN
- Stock Information
- Founded
- CRT 1991
- XGN 2002
- Country
- CRT United States
- XGN United States
- Employees
- CRT N/A
- XGN N/A
- Industry
- CRT Oil & Gas Production
- XGN Medical Specialities
- Sector
- CRT Energy
- XGN Health Care
- Exchange
- CRT Nasdaq
- XGN Nasdaq
- Market Cap
- CRT 59.2M
- XGN 50.7M
- IPO Year
- CRT 1992
- XGN 2019
- Fundamental
- Price
- CRT $11.05
- XGN $4.18
- Analyst Decision
- CRT
- XGN Buy
- Analyst Count
- CRT 0
- XGN 1
- Target Price
- CRT N/A
- XGN $7.00
- AVG Volume (30 Days)
- CRT 27.6K
- XGN 70.4K
- Earning Date
- CRT 01-01-0001
- XGN 11-12-2024
- Dividend Yield
- CRT 9.77%
- XGN N/A
- EPS Growth
- CRT N/A
- XGN N/A
- EPS
- CRT 1.13
- XGN N/A
- Revenue
- CRT $7,711,133.00
- XGN $55,751,000.00
- Revenue This Year
- CRT N/A
- XGN $9.98
- Revenue Next Year
- CRT N/A
- XGN $13.63
- P/E Ratio
- CRT $9.19
- XGN N/A
- Revenue Growth
- CRT N/A
- XGN 8.00
- 52 Week Low
- CRT $8.88
- XGN $1.30
- 52 Week High
- CRT $20.50
- XGN $4.83
- Technical
- Relative Strength Index (RSI)
- CRT 65.66
- XGN 70.53
- Support Level
- CRT $9.78
- XGN $2.62
- Resistance Level
- CRT $11.28
- XGN $4.83
- Average True Range (ATR)
- CRT 0.34
- XGN 0.36
- MACD
- CRT 0.12
- XGN 0.15
- Stochastic Oscillator
- CRT 94.94
- XGN 62.51
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States based trust. Its principal asset is the net profits interests. The net profits interests are derived from producing royalty, overriding royalty interests, and working interests properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.